Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants With Preclinical Alzheimer's Disease

NCT06544616 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT06544616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06544616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants With Preclinical Alzheimer's Disease
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 22, 2024
Completion date
January 5, 2027
Enrollment
55 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease